What happens with Mounjaro week by week

Weeks one to four: your body is adjusting, not failing

Picture this: it's a Monday evening, you've done your first injection, and by Wednesday morning you feel mildly queasy before breakfast. That nausea is not a sign something has gone wrong. It is the most commonly reported experience in the early weeks, as tirzepatide begins slowing gastric emptying and signalling fullness through two separate gut-hormone pathways. For most people the queasiness settles within days, particularly if meals are kept small and low in fat.

Appetite often changes noticeably even at 2.5 mg. Many people describe food simply feeling less urgent, or finding they feel full after considerably less than usual. The scales, though, may not have much to show yet. The opening weeks are largely about tolerability rather than measurable weight change. Fatigue, mild headache and occasional constipation are also reported during this settling-in phase. These are recognised in the NHS patient information for tirzepatide and tend to resolve without intervention for most people.

If you want a closer look at what that very first week feels like day to day, our page on starting Mounjaro for the first time covers it in detail. The main thing weeks one to four ask of you is patience. The medicine is working even when the evidence is quiet.

Weeks five to eight: the scales start to move, then sometimes stall

By the fifth or sixth week, many people begin to see consistent movement on the scales. Appetite suppression tends to feel more established at this point, and eating patterns often shift in ways that happen almost automatically rather than through conscious restriction. This is also, for many, the period when a plateau arrives unexpectedly.

A temporary stall around weeks five to eight is a well-recognised pattern, and it is not a sign the medicine has stopped working. The body adapts to a lower calorie intake by adjusting its resting energy use; the plateau often breaks when the dose increases. If you are experiencing this phase, the detail on our week-five experience may reassure you, as may the broader account on our week-six page. Side effects at this stage are usually less prominent than in week one, though a dose increase can briefly bring mild nausea back.

Weight loss varies considerably between individuals. In the SURMOUNT-1 trial, involving 2,539 adults, average body-weight reduction over 72 weeks at the 15 mg maintenance dose was around 20 to 21 percent; the losses at earlier time points and lower doses were more modest, as you would expect given the gradual titration. Published in the New England Journal of Medicine, the trial underpins NICE's recommendation of tirzepatide for weight management.

Weeks nine onwards: dose increases and building momentum

From around week nine, many people are titrating to 5 mg or beyond. Each step up tends to produce a fresh wave of appetite suppression, and often a renewed period of more noticeable weight loss. The pattern of modest plateau followed by progress following a dose increase repeats across the schedule. It helps to think of the treatment as a series of phases rather than a smooth downward line.

Our page tracking Mounjaro weight loss by week puts numbers to this in more detail. The broader picture of what longer-term treatment looks like, including how results typically develop through each phase of titration, is covered in our Mounjaro and weight loss overview. For context on how tirzepatide's dual mechanism drives these changes biologically, that page explains how activating both GIP and GLP-1 receptors differs from older single-pathway medicines.

Physical activity and protein intake matter more, not less, as weight comes off. Preserving muscle during a calorie deficit is something your prescriber and, where relevant, a dietitian can guide you on individually.

When the weeks feel harder than expected

Some weeks are genuinely difficult. Nausea that is more persistent than expected, a plateau that does not break, or uncertainty about whether a symptom needs attention all come up in practice. Side effects that are severe, persistent, or include anything like intense stomach pain that spreads to the back warrant prompt medical attention, not a wait-and-see approach. The MHRA also maintains the Yellow Card reporting scheme, where patients can flag any unexpected reactions directly.

If you have specific questions about a particular point in your treatment, our week-seven page addresses some of the more common concerns that arrive around the two-month mark. And if the cost of ongoing treatment is something you are weighing up, the Mounjaro pricing page gives an honest breakdown of what private treatment involves. For anything that needs a direct clinical eye, our prescribers are here.